A Memorial Sloan Kettering Cancer Center-led team has followed more than 50 patients for more than two years after receiving immunotherapy, Time reports.
The analysis of HER2 and HER3 mutation carriers emphasizes how these studies can lead both to broadening and to narrowing of the patient populations for targeted drugs.
Some industry players are accusing CMS of advancing backdoor LDT regulation by proposing to cover NGS tests with FDA approval/clearance, except in a limited setting.
Researchers genotyped advanced cancer patients treated with immunotherapies and found that homozygosity at HLA loci was linked to decreased survival.
Memorial Sloan Kettering Cancer Center also hopes its partnership with analytics vendor Cota will help it prepare for value-based reimbursement.
The authorization implements regulatory strategies the FDA advanced with industry stakeholders, though labs may still be more inclined to take the CLIA route, as long as it is available.
The agency said that its action on MSK IMPACT "advances a policy framework that paves the way for the efficient review and availability of other NGS-based cancer profiling tools."
Analytics vendor Cota will classify records from Memorial Sloan Kettering in hopes of improving cancer care and research.
Pathoquest will compare its iDtect blood test with standard testing methods to identify microbes causing infections in patients with febrile neutropenia.
Researchers will use the company's Colvera assay to track biomarkers in rectal cancer patients before, during, and after treatment.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.